Vertex Pharmaceuticals Incorporated (VRTX) Current Ratio: 2.90
Is Vertex Pharmaceuticals Incorporated’s current ratio high or low?
Vertex Pharmaceuticals Incorporated's current ratio of 2.90 is 25% below its 5-year average of 3.87, near the low end of its 5-year range (2.69–4.83).
The current ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 2.90 as of Wednesday, June 10, 2026. It is above its 12-month average by 3.76% (2.79).
VRTX Current Ratio Chart
VRTX Average Current Ratio Chart
VRTX Current vs Average Current Ratio Chart
VRTX Current Ratio Metrics
CURRENT RATIO
2.90
CURRENT RATIO AVG TTM
2.79
CURRENT RATIO AVG 3Y
3.60
CURRENT RATIO AVG 5Y
3.87
CURRENT RATIO AVG 10Y
3.51
CURRENT RATIO AVG 15Y
3.51
CURRENT RATIO AVG 20Y
3.53
CURRENT VS TTM AVG
+3.76%
CURRENT VS 3Y AVG
-19.50%
CURRENT VS 5Y AVG
-25.00%
CURRENT VS 10Y AVG
-17.38%
CURRENT VS 15Y AVG
-17.28%
CURRENT VS 20Y AVG
-17.80%
VRTX Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 2.90 | 2.79 | 3.60 | 3.87 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.26 | 1.25 | 1.30 | 1.38 |
| Medtronic plc (MDT) | $103.04B | 0.00 | 1.94 | 2.03 | 2.16 |
| CVS Health Corporation (CVS) | $125.16B | 0.84 | 0.82 | 0.86 | 0.88 |
| Danaher Corporation (DHR) | $130.25B | 1.87 | 1.64 | 1.71 | 1.69 |
| Elevance Health Inc. (ELV) | $87.43B | 1.24 | 1.17 | 1.08 | 1.07 |
| Cigna Corporation (CI) | $78.25B | 0.85 | 0.84 | 0.80 | 0.80 |
| Pfizer Inc. (PFE) | $146.36B | 1.16 | 1.17 | 1.11 | 1.20 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 4.87 | 4.47 | 4.53 | 5.01 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 1.68 | 1.64 | 1.50 | 1.45 |
Liquidity Analysis
Current Ratio
2.90
Quick Ratio
2.46
Vertex Pharmaceuticals Incorporated Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Current Ratio FAQ
- What is the current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The current ratio for VRTX stock is 2.90.
- Is Vertex Pharmaceuticals Incorporated's current ratio high or low?
- Vertex Pharmaceuticals Incorporated's current ratio of 2.90 is 25% below its 5-year average of 3.87, near the low end of its 5-year range (2.69–4.83).
- What is the TTM average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average current ratio for VRTX stock is 2.79.
- What is the 3Y average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average current ratio for VRTX stock is 3.60.
- What is the 5Y average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average current ratio for VRTX stock is 3.87.
- What is the 10Y average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average current ratio for VRTX stock is 3.51.
- What is the 15Y average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average current ratio for VRTX stock is 3.51.
- What is the 20Y average current ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average current ratio for VRTX stock is 3.53.
Vertex Pharmaceuticals Incorporated Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 2.90 |
| 2024-12-31 | 2.69 |
| 2023-12-31 | 3.99 |
| 2022-12-31 | 4.83 |
| 2021-12-31 | 4.46 |
| 2020-12-31 | 4.33 |
| 2019-12-31 | 3.61 |
| 2018-12-31 | 3.43 |
| 2017-12-31 | 3.28 |
| 2016-12-31 | 2.31 |
| 2015-12-31 | 2.78 |
| 2014-12-31 | 4.20 |
| 2013-12-31 | 3.99 |
| 2012-12-31 | 3.67 |
| 2011-12-31 | 3.39 |
| 2010-12-31 | 2.23 |
| 2009-12-31 | 4.59 |
| 2008-12-31 | 4.01 |
| 2007-12-31 | 2.49 |
| 2006-12-31 | 3.07 |
| 2005-12-31 | 3.84 |
| 2004-12-31 | 2.61 |
| 2003-12-31 | 4.27 |
| 2002-12-31 | 10.16 |
| 2001-12-31 | 8.48 |
| 2000-12-31 | 7.20 |
| 1999-12-31 | 10.54 |
| 1998-12-31 | 18.98 |
| 1997-12-31 | 20.55 |
| 1996-12-31 | 18.62 |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani